Causality assessment for suspected DILI during clinical phases of drug development.
Saved in:
| Title: | Causality assessment for suspected DILI during clinical phases of drug development. |
|---|---|
| Authors: | Regev A; Global Patient Safety, Eli Lilly and Company, Lilly Corporate Center, Drop Code 2121, Indianapolis, IN, 46285, USA, regev_arie@lilly.com., Seeff LB, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, Watkins PB |
| Source: | Drug safety [Drug Saf] 2014 Nov; Vol. 37 Suppl 1, pp. S47-56. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9002928 Publication Model: Print Cited Medium: Internet ISSN: 1179-1942 (Electronic) Linking ISSN: 01145916 NLM ISO Abbreviation: Drug Saf Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1179-1942 |
|---|---|
| DOI: | 10.1007/s40264-014-0185-4 |
